NewsBenzingaOppenheimer avvia la copertura di Retension Pharmaceuticals con rating Outperform, annuncia un target di prezzo di 50 dollari Oppenheimer avvia la copertura di Retension Pharmaceuticals con rating Outperform, annuncia un target di prezzo di 50 dollari Benzinga 2026.11.03 17:13 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Z Squared Secures 5-Yr Option To Acquire Nearly 90 Acres Near Arkansas Campus, Terms Undisclosed Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday Truist Securities Downgrades Lucky Strike to Hold, Lowers Price Target to $4.35